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Clinical Features and Risk Classification of AML
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic stem/progenitor cells characterized by the rapid growth of abnormal white blood cells (blasts) 
that accumulate in the bone marrow and interfere with the production of normal blood cells. In contrast to the classical French-American-British (FAB) classification based on 
morphological appearance of blasts and their cytochemistry, the 2008 revised WHO classification of AML incorporates cytogenetic/genetic data that help to define biologically 
homogenous entities with prognostic and therapeutic relevance. Based on (cyto)genetic features of the AML, patients can be broadly classified into three risk groups, although 
patient-specific factors (age, performance status, comorbidity, etc.) are also key predictors of outcome. The “3+7” combination of daunorubicin and cytarabine is routinely used 
as induction chemotherapy for adult patients with AML, except PML-RARα leukemia, whereas molecular profiling is currently guiding postinduction therapeutic strategies. Com-
parison between adult and childhood AML shows that children have a higher incidence of chromosomal translocation, whereas normal (NK) and complex karyotype (CK)—the 
latter includes monosomal karyotype (MK) and is associated with dismal prognosis—are more prevalent in adults. While risk classification has advanced in the last decades, 
treatment of AML, except for t(15;17) leukemia, is only marginally improved, mainly by better supportive care, highlighting the need for novel therapies.
Molecular Mechanisms, Recurrent Gene Mutations, and Emerging Targeted Therapies in AML
PML-RARα from t(15;17) that exclusively associates with FAB-M3 (acute promyelocytic leukemia, APL) forms transcriptionally repressive complexes with retinoic X receptor 
(RXR), histone deacetylases (HDACs), enhancer of zeste (EZH2), and DNA methyltransferase (DNMT). All-trans retinoic acid (ATRA), which dissociates repressor complexes from 
PML-RARα and mediates its subsequent degradation, can effectively induce differentiation of APL cells. In combination with chemotherapy, ATRA achieves a 5 year overall 
survival of approximately 80%. While As2O3, which degrades PML-RARα, is commonly employed to treat relapsed patients, other targeted therapeutic agents, including HDAC 
inhibitors and RXR agonists, are being developed.
The MLL gene located at 11q23 has over 60 different fusion partners in AML. Wild-type MLL encodes a SET domain containing H3K4 histone methyltransferase but the SET 
domain is invariably replaced by the partner proteins in MLL fusions. All MLL fusions retain MLL’s N terminus that recruits Menin and the polymerase associated factor com-
plex (PAFc), which are critical for DNA binding, gene expression, and cellular transformation. Importantly, the fusion partners themselves recruit a variety of protein complexes 
involved in transcriptional elongation (p-TEFb) and/or histone methylation, e.g., DOT1L (H3K79) or PRMT1 (H4R3), resulting in aberrant transcriptional activation. Several novel 
targeted strategies are emerging for 11q23 AML, including inhibition of Menin, DOT1L, PRMT1, the histone acetylation reader BRD4, and LSD1 (although the mechanisms under-
lying the efficacy of LSD1 inhibition remain unclear).
Genes encoding core binding factors including AML1/RUNX1 and CBFβ are the most frequently rearranged ones in AML. Both core binding factor fusions complex with tran-
scriptional repressors, such as HDACs and NCoR, to suppress expression of downstream targets, thus prompting HDAC inhibitors as potential therapeutic agents. AML1-ETO 
fusions may also recruit transcriptional coactivators such as PRMT1 and histone acetyltransferase (HAT) CBP that are critical for transformation.
Going beyond microarray analyses, next-generation sequencing has been unravelling the vast genetic heterogeneity in AML and improving risk stratification, especially for 
NK-AML. This has led to the discovery of not only several candidate genes that could be classified under the conventional two-hit model (e.g., signaling and transcription factors) 
of myeloid leukemogeneis but also those involved in epigenetic regulation, spliceosome machinery, and the cohesin complex. Interestingly, some of the mutations identified in 
NK-AML such as those in FLT3 and c-KIT are also recurrent in AML with translocations. Several kinase inhibitors (e.g., FLT3i and dasatinib), anti-CD33 antibody conjugate gem-
tuzumab ozogamicin (GO), and hypomethylating agents are currently in clinical trials. The role of epigenetic modulation in AML has only started to be unraveled, even though the 
therapeutic benefit of hypomethylating agents in low blast AML predates our knowledge of the existence of these epigenetic regulator mutations.
Cell of Origin and Clonal Evolution Model of Leukemic Stem Cells
The cell of origin for AML stem cells is still unclear. However, studies using mouse models have shown that both hematopoietic stem cells (HSCs) and progenitor cells can be 
targeted by initiating events, such as MLL fusions and PML-RARα, to generate preleukemic stem cells (pre-LSCs) and, subsequently, LSCs with acquisition of additional coop-
erative events (e.g., FLT3). The origin of LSCs can influence the leukemia type and lineage, although the cellular origin’s role in treatment response remains to be determined. 
LSCs possess self-renewal ability and can give rise to short-lived progenies, which form the bulk of the leukemic population in the patient. LSCs and leukemic progenies can 
further evolve into different subclones by acquiring additional mutations, leading to multiple (epi)genetically different leukemic clones with various clone sizes in the patient at the 
time of diagnosis. After chemotherapy, the bulk of leukemic cells is eradicated, leading to clinical remission; however, chemoresistant LSCs persist in the patient at low levels. 
With time, LSCs, which may be shaped by the treatment, can give rise to different progenies again, reinitiating the disease. Thus, the dominant clone at the time of relapse may 
not necessarily be the same as the one at diagnosis. Self-renewal is a common feature shared by LSCs and HSCs. Pathways such as β-catenin and PTEN, which have differential 
effects on LSCs versus normal HSCs, may be key targets to eradicate LSCs.
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